VANCOUVER, BC — October 16, 2025 — Leads & Copy — INITIO Medical has been recognized by The International Centers for Precision Oncology Foundation (ICPO) as the first ICPO Theranostics Clinical Center of Excellence in Canada and North America. This accreditation underscores INITIO Medical’s commitment to advancing Theranostics and delivering high-quality, patient-centered care.
Odile Jaume, CEO of the ICPO Foundation, expressed enthusiasm about INITIO Medical Theranostics Center in Burnaby-Vancouver, Canada, joining the ICPO Center Network. The recognition was formally presented to Dr. Philip Cohen and Mina Bechai during the ICPO Reception & Center Certification Ceremony held in Barcelona last October 4, 2025 – right before the EANM annual meeting. ICPO plans to establish a collaboration with INITIO Medical stressing education through the ICPO Academy for Theranostics and INITIO’s on-site training resources, to further strengthen ICPO´s mission to advance Theranostics and expand patient access to this innovative therapy in Canada and globally.
Mina Bechai, Founder and CEO of INITIO Medical, said this recognition is a significant achievement for their team and a testament to their dedication to advancing precision oncology.
Dr. Francois Lamoureux, President of the Canadian Association of Nuclear Medicine (CANM), commented that the recognition of INITIO Medical is a proud moment for Canada and reflects the growing expertise and leadership in nuclear medicine within the country.
INITIO Medical Group is focused on advancing cancer care through radiopharmaceuticals and innovative clinical practices and partnerships. The ICPO Foundation aims to scale global patient access to Radiomolecular Precision Oncology.
Mina Bechai, Founder and CEO of INITIO Medical.
